ALZHEIMER DISEASE (AD)

This early-stage study tests the safety of an experimental vaccine called DUVAX in 24 healthy adults aged 40-65. The vaccine aims to train the immune system to attack two proteins linked to Alzheimer's disease. Researchers will monitor side effects and measure whether the vaccine…

This study tests whether low-dose radiation to the whole brain can slow down Alzheimer's disease in people with early-onset symptoms. Fifty participants will be randomly assigned to receive either the radiation treatment or a sham procedure. Researchers will track changes in memo…

This study tests whether a natural soy compound called genistein can slow down memory and thinking problems in people with mild cognitive impairment, often an early sign of Alzheimer's disease. Over 18 months, 150 adults aged 50+ will take either genistein or a placebo pill, with…

This study tests whether monoclonal antibody drugs can slow the progression of Alzheimer's disease in 120 people with mild cognitive impairment or mild Alzheimer's. Researchers will use PET scans to measure brain changes and see who benefits most from continued treatment, even if…

This study tests whether a daily supplement called tributyrin can slow memory decline in people with mild Alzheimer's disease. Over 12 weeks, 156 participants will take either tributyrin or a placebo, and researchers will measure changes in thinking skills, inflammation, and gut …

This study tests a faster way to diagnose Alzheimer's disease using blood tests, spinal taps, and brain scans. It involves 200 people with mild memory problems or early dementia. The goal is to see if a nurse-led screening tool can help get patients diagnosed much sooner than the…

This early-stage study tests whether a nasal spray made from neural stem cell exosomes (tiny particles that carry cell messages) is safe for people with moderate-to-severe early-onset Alzheimer's. Nine adults aged 50-75 will receive the spray at different frequencies for 28 days.…

This study looks at whether a lower dose of the drug lecanemab can work as well as the standard dose for people with early-stage Alzheimer's disease. About 140 adults aged 50-85 with mild cognitive impairment or mild Alzheimer's will be followed for 18 months. Researchers will co…

This study tests a new AI method to generate one type of brain scan (FDG PET) from another (amyloid PET) using existing data from 35 Alzheimer's patients. If successful, future patients might need only one scan instead of two, reducing radiation, cost, and time. No new procedures…

This study tests a program called Improving Dementia Care (IDC) to help primary care doctors identify dementia in patients who have memory concerns but no prior diagnosis. About 80 adults with mild cognitive issues will take part. The goal is to see if the program leads to more d…

This study looks at how caring for a family member with Alzheimer's disease affects caregivers' emotional health, daily life, and sense of burden, both during care and after the person dies. Researchers will interview and survey 66 current and former caregivers to understand thes…